Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma

Richard Riedel,Sebastian Michels,Carina Heydt,Janna Siemanowski,Carsten Kobe, Anne Bunck,Stephan Schäfer,Rieke N. Fischer,Matthias Scheffler,Diana S.Y. Abdulla,Lucia Nogová,Sophia Koleczko,Sabine Merkelbach-Bruse,Reinhard Büttner,Jürgen Wolf

Lung Cancer（2019）

引用 4|浏览57

暂无评分

摘要

•A patient with low-level MET amplification and high MET expression showed response to treatment with crizotinib.•Resistance was associated with loss of MET amplification and acquired KRAS mutation.•This points to the limitations of defining cut-offs for continuous biomarkers.

查看译文

关键词

Non-small cell lung cancer,Crizotinib,MET,TKI resistance

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要